Albireo AB
- Address
- S Annedal, Arvid Wallgrens Backe 20, Goteborgs Annedal
Sponsor Overview
Specializations
Pediatric Hepatobiliary Disorders
The sponsor concentrates on developing therapeutic interventions for rare cholestatic liver diseases affecting pediatric populations. Research efforts target conditions characterized by impaired bile flow and accumulation of toxic bile acids, which can lead to progressive liver damage in children. The organization's clinical programs address intrahepatic cholestasis and related hepatic complications that manifest during infancy and early childhood.
- Progressive Familial Intrahepatic Cholestasis (PFIC)
- Alagille Syndrome
- Biliary Atresia
- Bile Acid Synthesis Disorders
The therapeutic approach focuses on modulating bile acid homeostasis and reducing the hepatotoxic effects of accumulated bile acids in pediatric patients with genetic and congenital liver disorders. Clinical investigations evaluate treatments designed to interrupt the enterohepatic circulation of bile acids, thereby alleviating pruritus and preventing progressive liver injury in children with these debilitating conditions.
Rare Disease Therapeutics
The sponsor maintains a specialized focus on orphan diseases affecting the hepatobiliary system, particularly those with limited existing treatment options. Research initiatives target rare genetic disorders that disrupt normal bile acid metabolism and transport mechanisms, conditions that often present significant challenges in pediatric gastroenterology and hepatology.
- Genetic Cholestatic Syndromes
- Inborn Errors of Bile Acid Metabolism
- Rare Pediatric Liver Diseases
Clinical development programs emphasize interventions for conditions where bile acid toxicity drives disease pathology. The research addresses unmet medical needs in populations where conventional therapies provide inadequate symptom control or fail to prevent disease progression toward end-stage liver failure requiring transplantation.
Pruritus Management in Cholestatic Conditions
A significant component of the research portfolio addresses severe cholestatic pruritus, a debilitating symptom experienced by patients with bile flow disorders. Clinical studies investigate therapeutic strategies to reduce the intense itching that severely impacts quality of life and disrupts sleep patterns in affected children and their families.
- Bile Acid-Mediated Pruritus
- Symptom Control in Pediatric Cholestasis
- Quality of Life Improvement
The therapeutic mechanisms under investigation target the reduction of circulating pruritogenic bile acids and other mediators responsible for the intense itching characteristic of cholestatic liver diseases. Research evaluates both objective measures of disease markers and patient-reported outcomes to comprehensively assess treatment efficacy in managing this challenging symptom.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC) |  France Italy Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 8 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases1 trial280 other sponsors
Partnered Research Centres
8 centres- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Via Giovanbattista Pergolesi 33, 20900 Monza
- Address
- Villarroel 170, Department of Psychiatry and Psychology, Neuroscience Institute, 08036 Barcelona
- Address
- 184 Rue Du Faubourg Saint Antoine, 75571 Paris
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Albireo AB.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.